Global Microbial Fermentation Technology Market to Reach

New York, May 25, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Microbial Fermentation Technology Industry” – https://www.reportlinker.com/p05961041/?utm_source=GNW
Antibiotics, one of the segments analyzed in the report, is projected to record a 7.4% CAGR and reach US$16.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Enzymes segment is readjusted to a revised 3.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $8.2 Billion, While China is Forecast to Grow at 9.2% CAGR

The Microbial Fermentation Technology market in the U.S. is estimated at US$8.2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.2 Billion by the year 2030 trailing a CAGR of 9.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 4.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.2 Billion by the year 2030.

Select Competitors (Total 44 Featured)
– Amyris, Inc.
– Biocon Ltd.
– BioVectra Inc.
– Danone UK
– F. Hoffmann-La Roche AG
– Koninklijke DSM NV
– Lonza Group AG
– Novozymes A/S
– TerraVia Holdings, Inc.
– United Breweries Ltd.

Read the full report: https://www.reportlinker.com/p05961041/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Microbial Fermentation Technology – Global Key Competitors
Percentage Market Share in 2020 (E)
Competitive Market Presence – Strong/Active/Niche/Trivial for
Players Worldwide in 2020 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Microbial Fermentation Technology Market
Analysis of Annual Sales in US$ Million for Years 2014 through
2030

Table 2: World Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Geographic Region – USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2022 through 2030 and % CAGR

Table 3: World Historic Review for Microbial Fermentation
Technology by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2014 through 2021 and % CAGR

Table 4: World 16-Year Perspective for Microbial Fermentation
Technology by Geographic Region – Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2014,
2023 & 2030

Table 5: World Recent Past, Current & Future Analysis for
Antibiotics by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 6: World Historic Review for Antibiotics by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Revenues in US$ Million for Years 2014 through 2021
and % CAGR

Table 7: World 16-Year Perspective for Antibiotics by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 8: World Recent Past, Current & Future Analysis for
Enzymes by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 9: World Historic Review for Enzymes by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Revenues in US$ Million for Years 2014 through 2021
and % CAGR

Table 10: World 16-Year Perspective for Enzymes by Geographic
Region – Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 11: World Recent Past, Current & Future Analysis for
Recombinant Proteins by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 12: World Historic Review for Recombinant Proteins by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR

Table 13: World 16-Year Perspective for Recombinant Proteins by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 14: World Recent Past, Current & Future Analysis for
Monoclonal Antibodies by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2022 through 2030 and % CAGR

Table 15: World Historic Review for Monoclonal Antibodies by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR

Table 16: World 16-Year Perspective for Monoclonal Antibodies
by Geographic Region – Percentage Breakdown of Value Revenues
for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa for Years 2014, 2023 & 2030

Table 17: World Recent Past, Current & Future Analysis for
Small Molecules by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 18: World Historic Review for Small Molecules by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR

Table 19: World 16-Year Perspective for Small Molecules by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 20: World Recent Past, Current & Future Analysis for
Vaccines by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 21: World Historic Review for Vaccines by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Revenues in US$ Million for Years 2014 through 2021
and % CAGR

Table 22: World 16-Year Perspective for Vaccines by Geographic
Region – Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 23: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 24: World Historic Review for Other Applications by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR

Table 25: World 16-Year Perspective for Other Applications by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 26: World Recent Past, Current & Future Analysis for
Contract Development & Manufacturing Organizations (CDMOs) by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2022 through 2030 and % CAGR

Table 27: World Historic Review for Contract Development &
Manufacturing Organizations (CDMOs) by Geographic Region – USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR

Table 28: World 16-Year Perspective for Contract Development &
Manufacturing Organizations (CDMOs) by Geographic Region –
Percentage Breakdown of Value Revenues for USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa for Years 2014, 2023 & 2030

Table 29: World Recent Past, Current & Future Analysis for
Biopharmaceutical Companies by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2022 through 2030 and % CAGR

Table 30: World Historic Review for Biopharmaceutical Companies
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR

Table 31: World 16-Year Perspective for Biopharmaceutical
Companies by Geographic Region – Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030

Table 32: World Recent Past, Current & Future Analysis for
Contract Research Organizations (CROs) by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2022 through 2030 and % CAGR

Table 33: World Historic Review for Contract Research
Organizations (CROs) by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2014 through 2021 and % CAGR

Table 34: World 16-Year Perspective for Contract Research
Organizations (CROs) by Geographic Region – Percentage
Breakdown of Value Revenues for USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa for
Years 2014, 2023 & 2030

Table 35: World Recent Past, Current & Future Analysis for
Academic & Research Institutes by Geographic Region – USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2022 through 2030 and % CAGR

Table 36: World Historic Review for Academic & Research
Institutes by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2014 through 2021 and % CAGR

Table 37: World 16-Year Perspective for Academic & Research
Institutes by Geographic Region – Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030

III. MARKET ANALYSIS

UNITED STATES
Microbial Fermentation Technology Market Presence – Strong/
Active/Niche/Trivial – Key Competitors in the United States
for 2023 (E)
Table 38: USA Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application – Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 39: USA Historic Review for Microbial Fermentation
Technology by Application – Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR

Table 40: USA 16-Year Perspective for Microbial Fermentation
Technology by Application – Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030

Table 41: USA Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use – Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 42: USA Historic Review for Microbial Fermentation
Technology by End-Use – Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR

Table 43: USA 16-Year Perspective for Microbial Fermentation
Technology by End-Use – Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030

CANADA
Table 44: Canada Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application – Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 45: Canada Historic Review for Microbial Fermentation
Technology by Application – Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR

Table 46: Canada 16-Year Perspective for Microbial Fermentation
Technology by Application – Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030

Table 47: Canada Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use – Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 48: Canada Historic Review for Microbial Fermentation
Technology by End-Use – Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR

Table 49: Canada 16-Year Perspective for Microbial Fermentation
Technology by End-Use – Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030

JAPAN
Microbial Fermentation Technology Market Presence – Strong/
Active/Niche/Trivial – Key Competitors in Japan for 2023 (E)
Table 50: Japan Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application – Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 51: Japan Historic Review for Microbial Fermentation
Technology by Application – Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR

Table 52: Japan 16-Year Perspective for Microbial Fermentation
Technology by Application – Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030

Table 53: Japan Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use – Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 54: Japan Historic Review for Microbial Fermentation
Technology by End-Use – Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR

Table 55: Japan 16-Year Perspective for Microbial Fermentation
Technology by End-Use – Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030

CHINA
Microbial Fermentation Technology Market Presence – Strong/
Active/Niche/Trivial – Key Competitors in China for 2023 (E)
Table 56: China Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application – Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 57: China Historic Review for Microbial Fermentation
Technology by Application – Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR

Table 58: China 16-Year Perspective for Microbial Fermentation
Technology by Application – Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030

Table 59: China Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use – Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 60: China Historic Review for Microbial Fermentation
Technology by End-Use – Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR

Table 61: China 16-Year Perspective for Microbial Fermentation
Technology by End-Use – Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030

EUROPE
Microbial Fermentation Technology Market Presence – Strong/
Active/Niche/Trivial – Key Competitors in Europe for 2023 (E)
Table 62: Europe Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Geographic Region –
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 63: Europe Historic Review for Microbial Fermentation
Technology by Geographic Region – France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets – Independent Analysis
of Annual Revenues in US$ Million for Years 2014 through 2021
and % CAGR

Table 64: Europe 16-Year Perspective for Microbial Fermentation
Technology by Geographic Region – Percentage Breakdown of Value
Revenues for France, Germany, Italy, UK, Spain, Russia and Rest
of Europe Markets for Years 2014, 2023 & 2030

Table 65: Europe Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application – Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 66: Europe Historic Review for Microbial Fermentation
Technology by Application – Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR

Table 67: Europe 16-Year Perspective for Microbial Fermentation
Technology by Application – Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030

Table 68: Europe Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use – Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 69: Europe Historic Review for Microbial Fermentation
Technology by End-Use – Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR

Table 70: Europe 16-Year Perspective for Microbial Fermentation
Technology by End-Use – Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030

FRANCE
Microbial Fermentation Technology Market Presence – Strong/
Active/Niche/Trivial – Key Competitors in France for 2023 (E)
Table 71: France Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application – Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 72: France Historic Review for Microbial Fermentation
Technology by Application – Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR

Table 73: France 16-Year Perspective for Microbial Fermentation
Technology by Application – Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030

Table 74: France Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use – Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 75: France Historic Review for Microbial Fermentation
Technology by End-Use – Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR

Table 76: France 16-Year Perspective for Microbial Fermentation
Technology by End-Use – Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030

GERMANY
Microbial Fermentation Technology Market Presence – Strong/
Active/Niche/Trivial – Key Competitors in Germany for 2023 (E)
Table 77: Germany Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application – Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 78: Germany Historic Review for Microbial Fermentation
Technology by Application – Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR

Table 79: Germany 16-Year Perspective for Microbial
Fermentation Technology by Application – Percentage Breakdown
of Value Revenues for Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications for the Years 2014, 2023 & 2030

Table 80: Germany Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use – Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 81: Germany Historic Review for Microbial Fermentation
Technology by End-Use – Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR

Table 82: Germany 16-Year Perspective for Microbial
Fermentation Technology by End-Use – Percentage Breakdown of
Value Revenues for Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes for the Years 2014, 2023 & 2030

ITALY
Table 83: Italy Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application – Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 84: Italy Historic Review for Microbial Fermentation
Technology by Application – Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR

Table 85: Italy 16-Year Perspective for Microbial Fermentation
Technology by Application – Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030

Table 86: Italy Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use – Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 87: Italy Historic Review for Microbial Fermentation
Technology by End-Use – Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR

Table 88: Italy 16-Year Perspective for Microbial Fermentation
Technology by End-Use – Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030

UNITED KINGDOM
Microbial Fermentation Technology Market Presence – Strong/
Active/Niche/Trivial – Key Competitors in the United Kingdom
for 2023 (E)
Table 89: UK Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application – Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 90: UK Historic Review for Microbial Fermentation
Technology by Application – Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR

Table 91: UK 16-Year Perspective for Microbial Fermentation
Technology by Application – Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030

Table 92: UK Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use – Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 93: UK Historic Review for Microbial Fermentation
Technology by End-Use – Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR

Table 94: UK 16-Year Perspective for Microbial Fermentation
Technology by End-Use – Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030

SPAIN
Table 95: Spain Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application – Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 96: Spain Historic Review for Microbial Fermentation
Technology by Application – Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR

Table 97: Spain 16-Year Perspective for Microbial Fermentation
Technology by Application – Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030

Table 98: Spain Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use – Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes – Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR

Table 99: Spain Historic Review for Microbial Fermentation
Technology by End-Use – Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR

Table 100: Spain 16-Year Perspective for Microbial Fermentation
Technology by End-Use – Percentage Breakdown of Value Revenues

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05961041/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________